Thus, modulation of tumor proliferation and invasiveness through inhibiting the activation of AKT or MAPKs (ERK and p38α) mediated by HOXB7 expression may be a promising therapeutic target for GC prevention and therapy. The gene discussed is MAPK1; the disease is gastric cancer.